Supernus Pharmaceuticals Current Deferred Revenue Over Time
| SUPN Stock | USD 36.10 0.12 0.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Supernus Pharmaceuticals Performance and Supernus Pharmaceuticals Correlation. Supernus |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Supernus Pharmaceuticals and related stocks such as Prestige Brand Holdings, Evotec SE ADR, and Collegium Pharmaceutical Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBH | (2 M) | 836 K | 836 K | 836 K | 836 K | 836 K | 492 K | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 3 M | 1.9 M |
| EVO | 3.4 M | 18.2 M | 5.8 M | 6.3 M | 3.3 M | 8.9 M | 15.9 M | 19 M | 61.2 M | 73.4 M | 70.6 M | 126.8 M | 136.7 M | 107.9 M | 113.2 M |
| COLL | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | 4.9 M | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (14.4 M) | (13.7 M) |
| ANIP | 136.4 K | 47 K | 47 K | 47 K | 24 M | 24 M | 24 M | 24 M | 711 K | 451 K | 80 K | 87 K | 32.5 M | 37.4 M | 39.2 M |
| PAHC | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 33.9 M | 33.9 M | 41.4 M | 3.6 M | 52.8 M | 44.8 M | 58.9 M | 822 K | 54.9 M | 10.2 M | 9.7 M |
| PCRX | 2 M | 13.1 M | 972 K | 1 M | 1.4 M | 1.4 M | 595 K | 102 K | 71.8 M | 71.8 M | 71.1 M | 10.1 M | 34 M | 39.1 M | 41.1 M |
| RDY | 382 M | 39 M | 553 M | 678 M | 1.1 B | 659 M | 819 M | 982 M | 1.4 B | 1.9 B | 2 B | 2.6 B | 2 B | 1.4 B | 1.4 B |
| RGC | 4 M | 89.6 M | 102.2 M | 181.8 M | 188.2 M | 203.4 M | 192.7 M | 186.2 M | 186.2 M | 186.2 M | 186.2 M | 186.2 M | 186.2 M | 214.1 M | 224.8 M |
Supernus Pharmaceuticals and related stocks such as Prestige Brand Holdings, Evotec SE ADR, and Collegium Pharmaceutical Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Supernus Pharmaceuticals | SUPN |
| Classification | Obamacare Repeal |
| Location | Maryland; U.S.A |
| Exchange | NASDAQ Exchange |
USD 36.1
Check out Supernus Pharmaceuticals Performance and Supernus Pharmaceuticals Correlation. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Supernus Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.